Patents by Inventor Alison Murphy

Alison Murphy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080038102
    Abstract: A waste hauling system comprises a receptacle for holding waste, a drive system including a wheel for moving the receptacle and a drive motor mechanically coupled to the wheel, a power source configured to drive the motor, a sensor for receiving a signal for operating the drive system, and a remote device including a transmitter for sending the signal received by the sensor.
    Type: Application
    Filed: August 10, 2006
    Publication date: February 14, 2008
    Inventors: Michael James Murphy, Lynn Alison Murphy
  • Publication number: 20070293500
    Abstract: Quinazoline derivatives and their pharmaceutically acceptable salts are inhibitors of TGF? activity and are used to treat conditions characterized by enhanced TGF? activity.
    Type: Application
    Filed: June 19, 2007
    Publication date: December 20, 2007
    Inventors: Sundeep DUGAR, Sarvajit Chakravarty, Alison Murphy, Glenn McEnroe, Aurelia Conte, John Perumattam
  • Patent number: 7232824
    Abstract: Quinazoline derivatives have the formula: or the pharmaceutically acceptable salts thereof; wherein each of Z5, Z6, Z7 and Z8 is N or CH and wherein one or two Z5, Z6, Z7 and Z8 are N and wherein two adjacent Z positions cannot be N; wherein m and n are each independently 0–3; wherein R1 is independently OH, SH, NH2, OR, SR, NHR, halo or R-halide; wherein two adjacent R1 groups may be joined to form an aliphatic hetero cycle ring of 5–6 members; wherein R2 is independently R, halo, R-halide, OR-halide, NH2, CONH2 or CONHR; wherein R is optionally substituted C1–C12 alkyl, C1–C12 alkenyl, C1–C12 alkynyl, or aryl C1–C12 alkyl, containing 0–4 heteroatoms in place of a carbon in the carbon backbone, where the optional substituents are ?O, ?N, or OH; and wherein R3 is H or CH3. Such compounds are useful in pharmaceutical compositions and methods of treating conditions characterized by enhanced TGF? activity.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: June 19, 2007
    Assignee: Scios, Inc.
    Inventors: Sundeep Dugar, Sarvajit Chakravarty, Alison Murphy, Glenn McEnroe, Aurelia Conte, John J. Perumattam
  • Patent number: 7223766
    Abstract: Compounds in which a pyrimidine nucleus is bridged at the 5 and 6 position and are further substituted at positions 2 and 4 with substituents comprising aromatic moieties are useful in treating subjects with rheumatoid arthritis ameliorated by inhibition of TGF? activity.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: May 29, 2007
    Assignee: Scios, Inc.
    Inventors: Sundeep Dugar, Sarvajit Chakravarty, Aurelia Conte, Jonathan Axon, Glenn McEnroe, Alison Murphy
  • Publication number: 20070066632
    Abstract: Certain appropriately substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with excessive TGF? activity and certain viral disorders.
    Type: Application
    Filed: March 27, 2006
    Publication date: March 22, 2007
    Applicant: Scios, Inc.
    Inventors: Barry Hart, Sarvajit Chakravarty, Jonathan Axon, Alison Murphy, Glenn McEnroe
  • Publication number: 20060281763
    Abstract: Certain appropriately substituted forms of pyrimidine having a pyridylamine group at C-4 of the pyrimidine and an amide group on the pyridine ring are useful in the treatment of conditions associated with excessive TGF? activity.
    Type: Application
    Filed: March 27, 2006
    Publication date: December 14, 2006
    Inventors: Jonathan Axon, Sarvajit Chakravarty, Barry Hart, Glenn McEnroe, Alison Murphy, Karen Pontius, Peijue Sheng, Xiaojing Wang, Shanthi Yellapregada
  • Publication number: 20050096333
    Abstract: Quinazoline derivatives have the formula: or the pharmaceutically acceptable salts thereof; wherein each of Z5, Z6, Z7 and Z8 is N or CH and wherein one or two Z5, Z6, Z7 and Z8 are N and wherein two adjacent Z positions cannot be N; wherein m and n are each independently 0-3; wherein R1 is independently OH, SH, NH2, OR, SR, NHR, halo or R-halide; wherein two adjacent R1 groups may be joined to form an aliphatic hetero cycle ring of 5-6 members; wherein R2 is independently R, halo, R-halide, OR-halide, NH2, CONH2 or CONHR; wherein R is optionally substituted C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl, or aryl C1-C12 alkyl, containing 0-4 heteroatoms in place of a carbon in the carbon backbone, where the optional substituents are ?O, ?N, or OH; and wherein R3 is H or CH3. Such compounds are useful in pharmaceutical compositions and methods of treating conditions characterized by enhanced TGF? activity.
    Type: Application
    Filed: September 30, 2004
    Publication date: May 5, 2005
    Inventors: Sundeep Dugar, Sarvajit Chakravarty, Alison Murphy, Glenn McEnroe, Aurelia Conte, John Perumattam
  • Publication number: 20050004143
    Abstract: Compounds in which a pyrimidine nucleus is bridged at the 5 and 6 position and are further substituted at positions 2 and 4 with substituents comprising aromatic moieties are useful in treating subjects with conditions ameliorated by inhibition of TGF? activity.
    Type: Application
    Filed: March 26, 2004
    Publication date: January 6, 2005
    Inventors: Sundeep Dugar, Sarvajit Chakravarty, Aurelia Conte, Jonathan Axon, Glenn McEnroe, Alison Murphy
  • Publication number: 20040132730
    Abstract: Certain appropriately substituted forms of pyrimidine and triazine are useful in the treatment to conditions associated with enhanced TGF&bgr; activity.
    Type: Application
    Filed: September 10, 2003
    Publication date: July 8, 2004
    Inventors: Jonathan Axon, Sarvajit Chakravarty, Sundeep Dugar, Glenn McEnroe, Alison Murphy